Indian Scientists Engineer GlowCas9a CRISPR Protein to Revolutionise Gene Editing and Cancer Treatment
A team of Indian scientists from the Bose Institute in Kolkata has achieved a significant breakthrough in gene editing technology with the development of GlowCas9a — a novel CRISPR protein engineered to emit fluorescent light during the gene editing process. The innovation, which allows researchers to visually track CRISPR activity in real time, has the potential to dramatically improve the precision, safety, and therapeutic applications of gene editing, particularly in the treatment of genetic diseases and cancer.
Illuminating the Invisible: What GlowCas9a Does
CRISPR-Cas9 technology has transformed biological research since its development in 2012, enabling scientists to make precise cuts in DNA sequences and thereby modify genes with unprecedented accuracy. However, one of the persistent challenges in CRISPR research has been the difficulty of monitoring exactly when and where the Cas9 protein — the molecular “scissors” that cut the DNA — is active within a cell. This uncertainty has implications for both the efficiency and safety of gene editing, as off-target cuts can cause unintended mutations with potentially harmful consequences.
GlowCas9a addresses this challenge by incorporating a fluorescent reporter domain into the Cas9 protein structure. When the protein binds to its target DNA sequence and initiates cutting, the conformational change triggers fluorescence — literally causing the protein to glow. This allows researchers to observe gene editing activity in real time using fluorescence microscopy, providing immediate feedback on whether the CRISPR system is engaging with the intended target.
“Think of it as giving CRISPR a built-in indicator light,” explained Dr. Abhijit Datta, the lead researcher on the project. “Previously, we had to wait until after the editing was complete and then analyse the results to determine whether the cuts were accurate. With GlowCas9a, we can see the editing happening as it occurs, which fundamentally changes our ability to control and optimise the process.”
From Kolkata to the Global Stage
The Bose Institute, founded in 1917 by the pioneering physicist Jagadish Chandra Bose, has a distinguished history of scientific contribution, and the development of GlowCas9a adds a contemporary chapter to this legacy. The research team, comprising molecular biologists, structural biochemists, and bioengineers, spent over three years designing, synthesising, and validating the modified protein.
The key engineering challenge was to integrate the fluorescent domain without compromising the Cas9 protein’s catalytic activity — its ability to find, bind, and cut the target DNA sequence. Through iterative rounds of protein engineering and directed evolution, the team identified an insertion site that preserved full enzymatic function while enabling robust fluorescence upon DNA engagement.
The findings were published in a peer-reviewed international journal and have attracted attention from gene therapy researchers worldwide. Several international laboratories have expressed interest in licensing the GlowCas9a technology for use in their own gene editing programmes, reflecting the broad applicability of the innovation.
The breakthrough exemplifies the calibre of scientific talent being cultivated across Indian research institutions, efforts that extend to ISRO’s expanded science training programmes and the growing network of interdisciplinary research centres across the IIT system.
Implications for Cancer Treatment
The potential applications of GlowCas9a in oncology are particularly compelling. CRISPR-based cancer therapies — which aim to modify immune cells to better recognise and attack tumour cells, or to directly correct cancer-causing mutations — are among the most promising frontiers in precision medicine. However, the clinical translation of these approaches has been hampered by concerns about off-target editing, which could inadvertently introduce new mutations that promote rather than suppress cancer.
GlowCas9a’s real-time monitoring capability directly addresses this concern. By enabling researchers to verify that CRISPR is engaging only with the intended genomic targets, the technology could significantly reduce the risk of off-target effects and accelerate the regulatory pathway for CRISPR-based cancer therapies. Dr. Datta’s team has initiated preliminary studies examining GlowCas9a’s performance in editing immune cell populations, with early results described as “highly encouraging.”
“Cancer is fundamentally a disease of the genome — it arises from mutations in DNA,” Dr. Datta noted. “CRISPR gives us the ability to correct or exploit these mutations for therapeutic benefit. GlowCas9a makes this process safer and more predictable, which is essential for clinical applications where patient safety is paramount.”
Genetic Diseases: A Broader Horizon
Beyond oncology, GlowCas9a holds promise for the treatment of inherited genetic disorders, many of which are caused by single-gene mutations that are, in principle, correctable through gene editing. Conditions such as sickle cell disease, beta-thalassemia, cystic fibrosis, and Duchenne muscular dystrophy are among those being targeted by CRISPR researchers globally.
India, with its large and genetically diverse population, carries a significant burden of genetic diseases. The prevalence of haemoglobinopathies — including sickle cell disease and thalassemia — is particularly high in certain tribal and ethnic communities. GlowCas9a’s ability to improve the precision and monitoring of gene editing could be especially valuable in developing therapies tailored to the genetic profiles of these populations.
The Indian Council of Medical Research (ICMR) has been developing guidelines for clinical gene editing research, balancing the potential of CRISPR technology with ethical considerations around heritable genome modifications. The GlowCas9a platform, with its enhanced safety monitoring capabilities, could help navigate these regulatory considerations by providing more robust data on editing accuracy and specificity.
India’s Growing Biotechnology Ecosystem
The GlowCas9a development is part of a broader flowering of biotechnology innovation in India. The country’s biotech sector, valued at approximately $130 billion, has been growing at a compound annual rate of over 14 per cent, driven by strengths in biopharmaceuticals, agricultural biotechnology, and industrial enzymes. The government’s Biotechnology Industry Research Assistance Council (BIRAC) has supported hundreds of biotech start-ups and early-stage research projects, creating a pipeline of innovation that is beginning to yield globally significant results.
Indian researchers have also made notable contributions to CRISPR technology beyond GlowCas9a. Teams at the Indian Institute of Science, IIT Kanpur, and the National Centre for Biological Sciences have published research on novel guide RNA designs, CRISPR delivery mechanisms, and applications in agricultural genomics — areas that collectively expand the toolkit available to gene editing researchers worldwide.
The same spirit of scientific innovation that propels discoveries like GlowCas9a also drives India’s achievements in other domains, including the country’s world-leading wildlife conservation programmes that deploy cutting-edge technology for species monitoring and habitat management.
Looking Forward
The development of GlowCas9a by an Indian research team serves as both a scientific milestone and a statement of capability. As the global race to harness CRISPR technology for therapeutic benefit intensifies, India’s ability to contribute original innovations — rather than merely adopting those developed elsewhere — will be critical to its standing in the international scientific community and to the accessibility of gene editing therapies for its own population.
For the researchers at the Bose Institute, the next steps involve optimising GlowCas9a for specific therapeutic contexts, exploring its integration with emerging CRISPR variants such as base editors and prime editors, and establishing collaborative clinical research programmes with Indian medical institutions. The glow may be coming from a protein, but the light it casts illuminates a path toward a future where genetic diseases are not merely managed but cured.
- India’s AI Impact Summit 2026 Signals a Shift From Prototypes to Real-World Deployment - March 25, 2026
- New Heavy Particle Discovered at CERN in 2026: What It Means for the Future of Physics - March 24, 2026
- Gaganyaan 2026: India’s Human Spaceflight Programme Enters Its Most Critical Phase - March 24, 2026
